Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 02/08 03:50:21 pm
37.51 USD   +0.27%
02/03 ABBOTT LABORATO : Labs Acquires Kalila Medical
02/02 ABBOTT LABORATO : Labs to Acquire Alere for $5.8 Billion
02/02DJMedical-Device Firms Use Deals To Branch Out
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201320142015201620172018
Sales21 84820 24720 40520 50621 65022 882
Operating income (EBITDA)4 9745 862-5 2555 6916 250
Operating profit (EBIT)4 0464 3143 9793 9784 3934 710
Pre-Tax Profit (EBT)2 521-----
Net income2 5762 2844 4232 9783 4883 808
P/E ratio23,730,215,418,716,214,5
EPS ( $ )1,621,492,922,002,312,58
Dividend per Share ( $ )0,640,900,981,041,131,39
Yield1,67%2,00%2,18%2,79%3,02%3,71%
Reference price ( $ )38.3345.0244.9137.4137.4137.41
Announcement Date01/22/2014
12:44pm
01/29/2015
12:45pm
01/28/2016
12:31pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201320142015201620172018
Debt3 0863 782-3 4073 4853 053
Finance------
Operating income (EBITDA)4 9745 862-5 2555 6916 250
Leverage
(Debt/EBITDA)
0,62x0,65x-0,65x0,61x0,49x
Capital Expenditure1 1451 077-1 2061 2511 264
Book Value Per Share (BVPS)16,3 $14,3 $-14,7 $16,3 $17,4 $
Cash Flow per Share2,11 $2,41 $-2,92 $3,15 $3,69 $
Announcement Date01/22/2014
12:44pm
01/29/2015
12:45pm
01/28/2016
12:31pm
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 55 805 M$ -
Entreprise Value (EV) 59 212 M$ 59 291 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS) 18,7x 16,2x
Capitalization / Revenue 2,72x 2,58x
EV / Revenue 2,89x 2,74x
EV / EBITDA 11,3x 10,4x
Yield (DPS / Price) 2,79% 3,02%
Price to book (Price / BVPS) 2,54x 2,30x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 19,4% 20,3%
operating Leverage (Delta EBIT / Delta Sales) - 1,87x
Net Margin (Net Profit / Revenue) 14,5% 16,1%
ROA (Net Profit / Asset) 7,87% 9,27%
ROE (Net Profit / Equities) 14,5% 16,0%
Rate of Dividend 52,1% 49,0%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   5,88% 5,78%
Cash Flow / Sales 21,3% 21,7%
Capital Intensity (Assets / Sales) 1,84x 1,74x
Financial Leverage (Net Debt / EBITDA) 0,65x 0,61x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend